Nanostring Technologies 

$0.11
71
+$0.02+19.66% Thursday 20:00

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

財報

26Feb預期
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.95
-0.78
-0.61
-0.44
預期EPS
-0.53
實際EPS
不適用

財務

-125.37%利潤率
未盈利
2017
2018
2019
2020
2021
2022
127.26M營收
-159.54M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 NSTG 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
Show more...
執行長
R. Bradley Gray
員工
766
國家
US
ISIN
US63009R1095
WKN
000A1W1X2

上市

0 Comments

分享你的想法

FAQ

Nanostring Technologies 今天的股價是多少?
NSTG 目前價格為 $0.11 USD,過去 24 小時上漲了 +19.66%。在圖表上更密切關注 Nanostring Technologies 股價表現。
Nanostring Technologies 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Nanostring Technologies 的股票以代號 NSTG 進行交易。
Nanostring Technologies 去年的營收是多少?
Nanostring Technologies 去年的營收為 127.26MUSD。
Nanostring Technologies 去年的淨利是多少?
NSTG 去年的淨收益為 -159.54MUSD。
Nanostring Technologies 有多少名員工?
截至 April 01, 2026,公司共有 766 名員工。
Nanostring Technologies 位於哪個產業?
Nanostring Technologies從事於Manufacturing產業。
Nanostring Technologies 何時完成拆股?
Nanostring Technologies 最近沒有進行任何拆股。
Nanostring Technologies 的總部在哪裡?
Nanostring Technologies 的總部位於 US 的 Seattle。